Sensei Biotherapeutics Presents Promising SNS-101 Clinical Data at 2023 SITC Annual Meeting

DENVER, Colo., Nov 6, 2023 ( Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) presented, after Friday’s market close, initial monotherapy dose-escalation portion data from its Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), in a late-breaker poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The data suggests a potential best-in-class safety and pharmacokinetic profile among VISTA blocking antibodies and the potential to overcome long-standing pharmacological challenges encountered by first generation approaches to blocking VISTA.

Sensei Biotherapeutics is trading at $0.7943, up 0.1043 (+15.12), on 307.9K premarket shares traded.

Its 52-week range is $0.51 to $1.926. Its next resistance point is $0.87, but the volume needs to increase for it to make a meaningful move.

 24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.